Article: Nicotinamide Riboside Reverses Metabolic Dysfunction in Werner's Syndrome: Preclinical Findings

PrevNext
Metabolic Health Orphan Disease Preclinical

Nicotinamide Riboside Reverses Metabolic Dysfunction in Werner's Syndrome: Preclinical Findings

Synopsis

Werner syndrome (WS) features premature aging and metabolic dysfunction, yet mechanisms remain unclear. This study found that loss of the WRN protein accelerates early fat cell formation in both stem cells and zebrafish, partly through upregulation of SMARCA5, which regulates gene activity. Restoring WRN normalized SMARCA5 levels and fat cell development. Importantly, treatment with the NAD+ precursor nicotinamide riboside (NR) improved fat metabolism in both models, suggesting NR could help correct metabolic dysfunction in WS and potentially other aging-related conditions.

Journal

Cell & Bioscience

Share

Read more

Metabolic Health

Nicotinamide Riboside Shifts Human Fat Cells Toward Energy-Burning Beige Cells: Preclinical Findings

SynopsisBeige fat cells play key roles in organismal energy and metabolic balance. NR supplementation of human white fat cells derived from stem cells induced mitochondrial biogenesis and expressio...

Read more
COVID/Long-COVID

Nicotinamide Riboside Restores NAD+ Metabolism and Improves Recovery in COVID-19: Preclinical Findings

SynopsisSevere COVID-19 initially causes lung infection and inflammation. Some patients develop Post-Acute Sequelae of COVID (PASC), experiencing ongoing lung problems, fatigue, and cognitive issue...

Read more